META BIOMED said on the 16th that it will move in earnest into the biopolymer materials business, using its selection for a government research and development (R&D) support program as a springboard.
META BIOMED was selected as the lead research institution in the "medical new materials development" field under the Small and Medium Enterprises global leading technology development project "Jump-Up," overseen by the Ministry of SMEs and Startups. The program supports R&D based on strategic technology development and global cooperation, aiming to help small and midsize companies enter global markets and strengthen their technological competitiveness.
The project will run for about two years from Apr. 2026 to Mar. 2028. META BIOMED plans to invest a total of 1.6 billion won in research and development costs, including 1 billion won in government support.
Through this R&D, META BIOMED plans to advance its foundational technology for synthesizing medical polymer materials and, based on that, build a materials platform applicable across biohealth. The strategy is to encompass a high value-added product lineup expandable from microparticles to implantable devices and to expand its business scope beyond simple materials supply to applied products.
It also plans to secure mass-production technology to develop a hybrid composite material capable of high-load support for orthopedic use and to promote localization of high value-added materials.
META BIOMED completed its Materials Innovation Center last year and is pushing to reorganize its portfolio around new businesses, including biodegradable polymer materials, polymer fillers, skin boosters, and beauty devices. Through this, it aims to leap forward as a specialist in high-performance medical materials.
Marking its 35th anniversary last year, the company unveiled "Vision 2030," setting targets of 500 billion won in sales and 1 trillion won in corporate value by 2030. In particular, biodegradable polymer materials are core materials that can be used in various fields such as sutures and aesthetic fillers, and are expected to become the central pillar of future growth strategies.
META BIOMED President Oh Ji-su said, "Through this R&D project, we will further enhance the quality competitiveness of biodegradable polymer materials and secure a foundation for localization and entry into global markets," adding, "We will achieve continuous growth and enhance corporate value."